Geode Capital Management LLC Trims Position in Regeneron Pharmaceuticals, Inc. $REGN

Geode Capital Management LLC decreased its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.2% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 2,465,054 shares of the biopharmaceutical company’s stock after selling 4,531 shares during the quarter. Geode Capital Management LLC owned approximately 2.28% of Regeneron Pharmaceuticals worth $1,288,520,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in REGN. Activest Wealth Management grew its stake in Regeneron Pharmaceuticals by 110.5% during the first quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 21 shares in the last quarter. Costello Asset Management INC purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at about $27,000. Saudi Central Bank bought a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter worth about $31,000. Finally, Colonial Trust Advisors purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at approximately $32,000. Institutional investors own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on REGN shares. Canaccord Genuity Group reaffirmed a “buy” rating and set a $850.00 price target on shares of Regeneron Pharmaceuticals in a research note on Thursday, October 23rd. Weiss Ratings reiterated a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 8th. Jefferies Financial Group upped their price objective on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a “buy” rating in a research report on Wednesday, August 27th. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research report on Monday, August 4th. Finally, UBS Group lifted their price objective on shares of Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $796.57.

Insider Activity

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the firm’s stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at $1,538,843.04. The trade was a 73.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $681.72 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.06 and a quick ratio of 3.72. The stock has a market cap of $71.65 billion, a price-to-earnings ratio of 16.32, a price-to-earnings-growth ratio of 2.03 and a beta of 0.31. The firm has a 50-day moving average of $593.81 and a two-hundred day moving average of $569.58. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $823.56.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a return on equity of 13.76% and a net margin of 32.13%.The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. During the same quarter in the previous year, the business earned $12.46 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up .9% on a year-over-year basis. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 5th. Stockholders of record on Thursday, November 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.